Leukemia Society Offers Patients Peer Counseling

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 10
Volume 5
Issue 10

NEW YORK--The Leukemia Society of America has launched First Connection, a pilot program for helping newly diagnosed leukemia patients and their families receive counseling and information in the initial hours after diagnosis. Patients will be visited by a specially trained peer volunteer who has gone through a similar experience.

NEW YORK--The Leukemia Society of America has launched First Connection,a pilot program for helping newly diagnosed leukemia patientsand their families receive counseling and information in the initialhours after diagnosis. Patients will be visited by a speciallytrained peer volunteer who has gone through a similar experience.

Funded by a grant from Roche Labs, this free service will be offeredin Pittsburgh, Philadelphia, Columbia, SC, Birmingham, Charlotte,and St. Louis.

Articles in this issue
Anesthetic Interventions Rise When Anesthesiologists Join the Pain Team
Worldwide UN Survey Shows Many Impediments to Morphine Availability
Case-Based Pain Curriculum Used in Canadian Schools
Effective Physician and Patient Communication Is Essential in Palliative Care
Withdrawal Syndrome After Stopping Opioids Is Not Evidence of Drug Dependence, WHO Committee Says
Brief Pain Inventory and Faces Scale Perform Well in a Group of Low-Income, Primarily Black Cancer Patients
Whole-Body Vibration Within Specified Frequency Range May Provide Pain Relief
Pain Descriptions May Predict Presence of Neuropathic Pain
Neurotoxicity Related to High-Dose Opioid Therapy Can Be Managed
Epidural Morphine Relieves Pain in Advanced Cancer, But May Not Influence Quality of Life
Dr. Payne Urges Strategies to Overcome Barriers to Use of Cancer Pain Guidelines
Program Trains Community Opinion Leaders in Principles of Pain Control
Postmarketing Surveillance for Drug Abuse Supports Nonscheduled Status of Tramadol
Consider Quality of Life and Patient Preference When Choosing Pain Relief
Patients' Pain Anxiety Levels Vary Depending on the Type of Pain, the Patient's Gender, and Pain Duration

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
Related Content
Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Sunvozertinib Earns FDA Accelerated Approval in EGFR Exon 20+ NSCLC

Russ Conroy
July 2nd 2025
Article

Data from the phase 1/2 WU-KONG1 study support the accelerated approval of sunvozertinib in this population.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Comparing CAR T Safety, Efficacy in Relapsed/Refractory Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

The expert panel discussed the efficacy observed with cilta-cel in patients with relapsed/refractory multiple myeloma.

Stephen Liu, MD, and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Practice-Changing Lung Cancer Data From the 2025 ASCO Annual Meeting

Stephen V. Liu, MD;Joshua K. Sabari, MD
June 23rd 2025
Podcast

Stephen Liu, MD; and Joshua Sabari, MD, discuss the most intriguing non–small cell lung cancer and small cell lung cancer breakthroughs from the meeting.

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 (NCT03761108) trial.

Linvoseltamab Earns FDA Accelerated Approval for R/R Multiple Myeloma

Roman Fabbricatore
July 2nd 2025
Article

Data supporting the FDA decision came from the phase 1/2 LINKER-MM1 trial.

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.

SonoClear System Earns Breakthrough Designation for Intracranial Procedures

Roman Fabbricatore
July 2nd 2025
Article

The system showed enhanced diagnostic accuracy of intraoperative imaging, potentially improving the extent of resection while reducing residual disease.